MR Contrast Agent at High-Field MRI (3 Tesla)

Topics in Magnetic Resonance Imaging

Volumn 14, Issue 5, 2003, Pages 365-375

  Trattnig, Siegfried ^a   Ba Ssalamah, Ahmed ^a   Noebauer Huhmann, Iris Melanie ^a   Barth, Markus ^a   Wolfsberger, Stefan ^a   Pinker, Katja ^a   Knosp, Engelbert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

3 Tesla MRI; Brain tumors; Gadolinium; High field strength; Metastases; MR venography; MRI contrast agent

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

BRAIN METASTASIS; BRAIN TUMOR; CAVERNOUS SINUS; CONTRAST ENHANCEMENT; CRANIAL NERVE; DIAGNOSTIC IMAGING; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOPHYSIS ADENOMA; INTERMETHOD COMPARISON; MAGNETIC FIELD; MAGNETIC RESONANCE VENOGRAPHY; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO;

ADENOMA; BRAIN; BRAIN NEOPLASMS; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; PITUITARY NEOPLASMS;

EID: 0346874452     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200310000-00003     Document Type: Review

References (66)

1. Vaughan JT, Garwood M, Collins CM, et al. 7T vs. 4T: RF power, homogeneity and signal-to-noise comparison in head images. Magn Reson Med. 2001;46:24-30.
2. Bernstein MA, Huston J, Jack CR, et al. Routine clinical brain MR imaging at 3.0 T: initial experience. Proc Int Soc Mag Reson Med. 2000;8: 1994.
3. Bernstein MA, Huston J, Lin C, et al. High-resolution intracranial and cervical MRA at 3.0 T: technical considerations and initial experience. Magn Reson Med. 2001;46:955-962.
4. Thulborn KR. Clinical rationale for very-high-field (3.0 Tesla) functional magnetic resonance imaging. Top Magn Reson Imag. 1999;10:37-50.
5. Gonen O, Gruber S, Li BS, et al. Multivoxel 3D proton spectroscopy in the brain at 1.5 T versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR Am J Neuroradiol. 2001;22:1727-1731.
6. Hunsche S, Moseley ME, Stoeter P, et al. Diffusion-tensor MR imaging at 1.5 and 3.0 T: initial observations. Radiology. 2001;221:550-556.
7. Rinck PA, Fischer HW, Van der Elst D, et al. Field-cycling relaxometry: medical applications. Radiology. 1988;168:843-849.
8. Wood ML, Hardy PA. Proton relaxation enhancement. J Magn Res Imaging. 1993;3:149-156.
9. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by Gadolinium-based MR contrast agents. Eur Radiol. 1999;9:998-1004.
10. Wansapura JP, Holland SK, Dunn RS, et al. NMR relaxation times in the human brain at 3.0 Tesla. J Magn Res Imaging. 1999;9:531-538.
11. Elster AD. Field-strength dependence of Gadolinium enhancement: theory and implications. AJNR Am J Neuroradiol. 1994;15:1420-1423.
12. Akeson P, Vikhoff B, Stahlberg F, et al. Brain lesion contrast in MR Imaging: dependence of field strength and concentration of gadodiamide injection in patients and phantoms. Acta Radiol. 1997;38:14-18.
13. Chang KH, Ra DG, Han MH, et al. Contrast enhancement of brain tumors at different MR field strengths: comparison of 0.5 T and 2.0 T. AJNR Am J Neuroradiol. 1994;15:1413-1419.
14. Haustein J, Laniado M, Niendorf H-P, et al. Administration of Gadopentate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol. 1992;13:1199-1206.
15. Nöbauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 Tesla versus 1.5 Tesla. Invest Radiol. 2002;37:114-119.
16. Krautmacher C, Tschampa H, Born MC, et al. MRI of contrast enhancing brain tumors at 3 Tesla versus 1.5 Tesla: first clinical results evaluating T1-weighted SE, FFE and MDEFT sequences. Eur Congr Radiol. 2003;437.
17. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579-592.
18. Martini N. Operable lung cancer. CA Cancer J Clin. 1993;43:201-214.
19. Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol. 1988;45:741-744.
20. Healy ME, Hesselink J, Press GA, et al. Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology. 1987;165:619-624.
21. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology. 1991;180:485-491.
22. Runge VM, Kirsch JE, Burke VJ, et al. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging. 1992;2:9-18.
23. Ba-Ssalamah A, Noebauer-Huhmann IM, Pinker K, et al. The effect of contrast dose and field strength in the MR detection of brain metastases. Invest Radiol. 2003;38:414-421.
24. Yuh WT, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastases. AJNR Am J Neuroradiol. 1995;16:373-380.
25. Finelli DA, Hurst GC, Karaman BA, et al. Use of magnetization transfer for improved contrast on gradient-echo MR images of the cervical spine. Radiology. 1994;193:165-171.
26. Fahlbusch R, Buchfelder M. Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien). 1988;92:93-99.
27. Thapar K, Laws ER Jr. Pituitary surgery. In: Thapar K, Kovacs K, Scheithauer BW, et al., eds. Diagnosis and Management of Pituitary Tumors. Totowa, NJ: Humana, 2001;225-246
28. Knosp E, Kitz K, Steiner E, et al. Pituitary adenomas with parasellar invasion. Acta Neurochir Suppl (Wien). 1991;53:65-71.
29. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 1989; 25:927-930.
30. Taptas JN. The so-called cavernous sinus: a review of the controversy and its implications for neurosurgeons. Neurosurgery. 1982;11:712-717.
31. Dietemann JL, Kehrli P, Maillot C, et al. Is there a dural wall between the cavernous sinus and the pituitary fossa? Anatomical and MRI findings. Neuroradiology. 1998;40:627-630.
32. Kehrli P, Ali M, Reis M Jr, et al. Anatomy and embryology of the lateral sellar compartment (cavernous sinus) medial wall. Neurol Res. 1998;20: 585-592.
33. Cottier JP, Destrieux C, Brunereau L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000;215:463-469.
34. Scotti G, Yu CY, Dillon WP, et al. MR imaging of cavernous sinus involvement by pituitary adenomas. AJR Am J Roentgenol. 1988;151:799-806.
35. Steiner E, Imhof H, Knosp E. Gd-DTPA enhanced high resolution MR imaging of pituitary adenomas. Radiographics. 1989;9:587-598.
36. Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33:610-617.
37. Wolfsberger S, Ba-Ssalamah A, Pinker K, et al. Application of 3 Tesla magnetic resonance imaging for diagnosis and surgery of sellar lesions. Neurosurgery. (in press)
38. Rhoton AL Jr. The cavernous sinus, the cavernous venous plexus and the carotid collar. Neurosurgery. 2002;51:375-410.
39. Lang J. Skull Base and Related Structures. Stuttgart, Germany: Schattauer, 1995;186-191.
40. Umansky F, Nathan H. The lateral wall of the cavernous sinus: with special reference to the nerves related to it. J Neurosurg. 1982;56:228-234.
41. Korogi Y, Takahashi M, Sakamoto Y, et al. Cavernous sinus: correlation between anatomic and dynamic gadolinium-enhanced MR imaging findings. Radiology. 1991;180:235-237.
42. Daniels DL, Pech P, Mark L, et al. Magnetic resonance imaging of the cavernous sinus. AJR Am J Roentgenol. 1985;144:1009-1014.
43. Reichenbach JR, Venkatesan R, Schillinger DJ, et al. Small vessels in the human brain: MR venography with deoxyhemoglobolin as an intrinsic contrast agent. Radiology. 1997;204:272-277.
44. Reichenbach JR, Jonetz-Mentzel L, Fitzek C, et al. High-resolution blood oxygen-level dependent MR venography (HRBV): a new technique. Neuroradiology. 2001;43:364-369.
45. Reichenbach JR, Essig M, Haacke EM, et al. High-resolution venography of the brain using magnetic resonance imaging. MAGMA. 1998;6:62-69.
46. Essig M, Reichenbach JR, Schad LR, et al. High-resolution MR venography of cerebral arteriovenous malformations. Magn Reson Imaging. 1999;17:1417-1425.
47. Reichenbach JR, Barth M, Haacke EM, et al. High resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr. 2000;24:949-957.
48. Schad LR. Improved target volume characterization in stereotactic treatment planning of brain lesions by using high-resolution BOLD MR-venography. NMR Biomed. 2001;14:478-483.
49. Lee BC, Vo KD, Kido DK, et al. MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR Am J Neuroradiol. 1999;20:1239-1342.
50. Tan IL, van Schijndel RA, Pouwels PJ, et al. MR venography of multiple sclerosis. AJNR Am J Neuroadiol. 2000;21:1039-1042.
51. Barth M, Nöbauer-Huhmann IM, Reichenbach JR, et al. High resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first clinical experience and comparison with 1.5 Tesla. Invest Radiol. 2003;38:408-413.
52. Reichenbach JR, Haacke EM. High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed. 2001;14:453-467.
53. Novak V, Abduljalil A, Kangarlu A, et al. Intracranial ossifications and microangiopathy at 8 Tesla MRI. Magn Reson Imaging. 2001;19:1133-1137.
54. Abduljalil AM, Schmalbrock P, Novak V, et al. Phase venous vessels enhancement in high field brain MR imaging. Proc ISMRM. 2002;1045.
55. Lin W, Mukherjee P, An H, et al. Improving high-resolution MR bold venographic imaging using at T1 reducing contrast agent. J Magn Reson Imaging. 1999;10:118-123.
56. Tynninen O, Aronen HJ, Ruhala M, et al. MRI enhancement and microvascular density in gliomas: correlation with tumor cell proliferation. Invest Radiol. 1999;34:427-434.
57. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol. 2000;21:357-366.
58. Kuperman V, River JN, Lewis MZ, et al. Changes in T2*-weighted images during hyperoxia differentiate tumors from normal tissue. Magn Reson Med. 1995;33:318-325.
59. Karczmar GS, Kuperman VY, River NJ, et al. Magnetic resonance measurement of response to hyperoxia differentiates tumors from normal tissue and may be sensitive to oxygen consumption. Invest Radiol. 1994;29 (suppl 2):161-163.
60. Rodrigues LM, Maxwell RJ, McSheehy PM, et al. In vivo detection of ifosfamide by 31P-MRS in rat tumors: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas. Br J Cancer. 1997; 75:62-68.
61. Robinson SP, Howe FA, Griffiths JR. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 1995;33:855-859.
62. Robinson SP, Collingridge DR, Howe FA, et al. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed. 1999;12:98-106.
63. Howe FA, Robinson SP, Rodrigues LM, et al. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging. 1999;17:1307-1318.
64. Howe FA, Robinson SP, McIntyre DJ, et al. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumors. NMR Biomed. 2001;14:497-506.
65. McSheehy PM, Robinson SP, Ojugo AS, et al. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 1998;58:1185-1194.
66. Robinson SP, Howe FA, Rodrigues LM, et al. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol. 1998;8:197-207.